EU
IOVA icon

Emory University’s Iovance Biotherapeutics IOVA Stock Holding History

Emory University’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-131,041
Closed -$3.21M – 32
2019
Q2 		$3.21M Sell
131,041
-99,851
-43% -$1.5M 2.26% 4
2019
Q1 		$2.2M Sell
230,892
-16,750
-7% -$163K 1.54% 27
2018
Q4 		$2.19M Buy
247,642
+61,727
+33% +$595K 1.73% 15
2018
Q3 		$2.09M Buy
185,915
+10,318
+6% +$146K 1.37% 36
2018
Q2 		$2.25M Buy
+175,597
New +$2.57M 1.49% 28

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emory University's IOVA Position: Q3 2019 in Review

Emory University sold out of Iovance Biotherapeutics (IOVA) in Q3 2019, closing a stake of 131,041 shares — an estimated $3.21M sold.

Emory University first reported a position in IOVA in Q2 2018 and held it in 5 quarters. The position peaked at $3.21M in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Emory University reported no remaining Iovance Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Emory University sold 131,041 Iovance Biotherapeutics shares in Q3 2019, an estimated $3.21M.
  • Emory University first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 5 quarters.
  • Emory University's Iovance Biotherapeutics position peaked at $3.21M in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Emory University's 13F filing for Q3 2019, filed 14 Nov 2019.